Literature DB >> 1393809

Long-term course of antimalarial maculopathy after cessation of treatment.

M Easterbrook1.   

Abstract

Since 1980 I have examined some 1650 patients for the presence or absence of antimalarial maculopathy. Bilateral, irreversible visual field defects have been diagnosed is 62 patients, 37 of whom have been followed for at least 4 years. The 22 patients who presented with relative scotomas did not lose central visual acuity; over a median follow-up period of 6.0 years 33 (75%) of the eyes maintained their visual field, 5 (11%) showed some improvement in visual field, 4 (9%) lost some visual field, and 2 (4%) manifested small absolute scotomas. Nine (60%) of the 15 patients who presented with absolute scotomas were symptomatic. Over a median follow-up period of 8.8 years 19 (63%) of the eyes in this group lost one or more lines of visual acuity, including 4 (13%) that became legally blind; 19 (63%) lost field owing to an increase in the size of the absolute scotomas (13 eyes) or the development of new absolute scotomas (6 eyes). The results suggest that the visual prognosis is excellent if antimalarial therapy is stopped at an early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393809

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  16 in total

1.  Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine.

Authors:  Emrah Kan; Konuralp Yakar; Mehmet Derya Demirag; Mustafa Gok
Journal:  Int Ophthalmol       Date:  2017-07-10       Impact factor: 2.031

2.  Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.

Authors:  Paul Salu; André Uvijls; Pierre van den Brande; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2010-04-16       Impact factor: 2.379

3.  Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.

Authors:  S Pasadhika; G A Fishman; D Choi; M Shahidi
Journal:  Eye (Lond)       Date:  2010-04-16       Impact factor: 3.775

4.  [Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].

Authors:  R Bergholz; K Rüther; H Tillack; A M Joussen; J Schroeter
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

Review 5.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

6.  A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy.

Authors:  Vivienne C Greenstein; Luz Amaro-Quireza; Evelyn S Abraham; Rithambara Ramachandran; Stephen H Tsang; Donald C Hood
Journal:  Doc Ophthalmol       Date:  2014-12-12       Impact factor: 2.379

Review 7.  A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.

Authors:  Nathalie Costedoat-Chalumeau; Bertrand Dunogué; Gaëlle Leroux; Nathalie Morel; Moez Jallouli; Véronique Le Guern; Jean-Charles Piette; Antoine P Brézin; Ronald B Melles; Michael F Marmor
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

8.  Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?

Authors:  Samuel K Shinjo; Otacílio O Maia; Vivian A P Tizziani; Celso Morita; Jussara A L Kochen; Walter Y Takahashi; Ieda M M Laurindo
Journal:  Clin Rheumatol       Date:  2007-01-31       Impact factor: 3.650

10.  Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine.

Authors:  Yigit Ulviye; Tugcu Betul; Tarakcioglu Hatice Nur; Celik Selda
Journal:  Indian J Ophthalmol       Date:  2013-04       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.